Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting

被引：0
|
作者：
Murthy, Rashmi Krishna
Varma, Ankur
Mishra, Priyankana
Hess, Kenneth R.
Young, Elliana J.
Murray, James L.
Koenig, Kimberly Higginbotham
Green, Marjorie C.
Moulder, Stacy L.
Melhem-Bertrandt, Amal
Booser, Daniel J.
Valero, Vicente
Hortobagyi, Gabriel N.
Esteva, Francisco J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [22] Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer
    Yada Kanjanapan
    Sheau Wen Lok
    Peter Gibbs
    Richard De Boer
    Belinda Yeo
    Sally Greenberg
    Frances Barnett
    Louise Knott
    Gary Richardson
    Rachel Wong
    Michelle Nottage
    Ian M. Collins
    Javier Torres
    Janine Lombard
    Julie Johns
    Michael Harold
    Laeeq Malik
    Breast Cancer Research and Treatment, 2020, 184 : 87 - 95
  • [23] Budget impact analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Aultman, R.
    Krzakowski, M.
    Pienkowski, T.
    Drosik, K.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2007, 10 (03) : A124 - A124
  • [24] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [25] Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
    Zardavas, Dimitrios
    Pugliano, Lina
    Ades, Felipe
    Bozovic-Spasojevic, Ivana
    Capelan, Marta
    de Azambuja, Evandro
    BREAST CANCER MANAGEMENT, 2012, 1 (03) : 217 - 233
  • [26] Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
    Veeraraghavan, Jamunarani
    Liao, Fu-Tien
    Qin, Lanfang
    Gordon, Tia
    Raghavan, Alekya
    Sabotta, Caroline
    Kaplan, Rachel
    Gutierrez, Carolina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2024, 84 (03)
  • [27] Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
    Yoshikawa, Ayumu
    Nakamura, Yoshiaki
    CANCERS, 2023, 15 (01)
  • [28] Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY
    Slamon, Dennis J.
    Buyse, Marc
    Press, Michael F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 663 - 665
  • [29] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
    Diogo Mendes
    Carlos Alves
    Noémia Afonso
    Fátima Cardoso
    José Luís Passos-Coelho
    Luís Costa
    Sofia Andrade
    Francisco Batel-Marques
    Breast Cancer Research, 17
  • [30] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review
    Mendes, Diogo
    Alves, Carlos
    Afonso, Noemia
    Cardoso, Fatima
    Passos-Coelho, Jose Luis
    Costa, Luis
    Andrade, Sofia
    Batel-Marques, Francisco
    BREAST CANCER RESEARCH, 2015, 17
12345